KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardlytics (CDLX) Return on Sales (2017 - 2025)

Historic Return on Sales for Cardlytics (CDLX) over the last 9 years, with Q3 2025 value amounting to 1.4%.

  • Cardlytics' Return on Sales rose 7700.0% to 1.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.44%, marking a year-over-year increase of 4900.0%. This contributed to the annual value of 0.68% for FY2024, which is 2400.0% down from last year.
  • Per Cardlytics' latest filing, its Return on Sales stood at 1.4% for Q3 2025, which was up 7700.0% from 0.15% recorded in Q2 2025.
  • In the past 5 years, Cardlytics' Return on Sales ranged from a high of 0.49% in Q1 2022 and a low of 4.59% during Q4 2022
  • For the 5-year period, Cardlytics' Return on Sales averaged around 0.73%, with its median value being 0.31% (2023).
  • Its Return on Sales has fluctuated over the past 5 years, first tumbled by -44500bps in 2022, then surged by 34500bps in 2023.
  • Quarter analysis of 5 years shows Cardlytics' Return on Sales stood at 0.13% in 2021, then tumbled by -3389bps to 4.59% in 2022, then skyrocketed by 75bps to 1.13% in 2023, then surged by 81bps to 0.21% in 2024, then crashed by -563bps to 1.4% in 2025.
  • Its Return on Sales was 1.4% in Q3 2025, compared to 0.15% in Q2 2025 and 0.21% in Q1 2025.